By Ben Glickman
Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of biliary tract cancer.
Zymeworks' stock was up 8.3% to $15.75 in pre-market trading. Shares are up about 40% this year as of Wednesday's close.
The U.S. Food and Drug Administration granted Ziihera, an antibody treatment, accelerated approval for injection for intravenous use in treating adults with certain forms of biliary tract cancer.
Zymeworks first developed the molecule, and in 2022 entered a license and collaboration deal with Jazz for exclusive development and commercialization rights to the compound in most countries. Under the licensing deal, Zymeworks has earned a milestone payment of $25 million based on FDA approval of Ziihera in BTC.
Jazz shares were up about 2.3% in pre-market trading.
BeiGene has the compound's license in Asia Pacific territories.
The company is still eligible for up to $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments from Jazz. Zymeworks will also receive tiered royalties on sales.
Zymeworks said Ziihera was the first candidate in its pipeline to receive FDA approval.
Ziihera, known by generic name zanidatamab, is also being evaluated as a treatment option for patients with other solid tumors.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 21, 2024 09:30 ET (14:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。